Thus, several trials involving many BACE inhibitors were halted due to their lack of efficacy and safety concerns [23]. Nevertheless, the BACE inhibitors reducing Aβ oligomers within the CSF in phase-I/II trials underscores their potential to slow down the progression of AD [23]. Here, BACE1 is linked to Alzheimer disease.